This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Labs Has Fallen and It Can't Get Up

For this reason, I can only take management at its word. But the logic in the rest of the business was still a tough sell, given the strong numbers I've seen from Johnson & Johnson (JNJ) and Boston Scientific (BSX). The company didn't even crack 1% growth in molecular diagnostics. Even more heart-wrenching was the 1% growth in the established pharmaceuticals business.

In odd fashion, management claimed that the 1% growth was due to a 10% operational growth in key international markets. I don't see how that made any sense. The good news was that Abbott found strong support in the diagnostic area. That segment was up more than 8% year over year.

While it's encouraging that the medical optics business advanced close to 15%, that segment is not nearly as large as the devices business. In fairness, the 4% growth is a step in the right direction. But the 4% decline in diabetes killed any sort of glass half-full optimism I could have had.

This narrative hasn't changed. And I don't see how the Street still justifies giving Abbott a higher premium than a top-notch performer like Roche (RHHBY). Not to mention, with the recall in effect due to the contamination, Abbott's dominant nutrition business is in danger of becoming malnourished.

The way I see it, the company has now reached a point where management should start thinking about a strategic acquisition or two. This is the only way for Abbott to catch up to Johnson & Johnson and Boston Scientific in areas like devices.

And if the company truly cares about shoring up its deficit in diagnostics, which was steady this quarter, significant capital reinvestments need to be made -- especially since Johnson & Johnson has all but given up that market. Rivals like Roche are just not going to sit idle and wait for Abbott to make up its mind.

At best these shares are a hold. The only way to justify buying this stock -- and then, only on a pullback -- is for management to demonstrate better operating balance among all business segments.

We're not there yet.

At the time of publication, the author held no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $37.46 0.13%
AAPL $95.01 1.05%
FB $97.75 -6.10%
GOOG $682.74 -0.12%
TSLA $142.31 -12.00%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs